Listen to today’s podcast here!
Researchers recently found that cardiac natriuretic peptides (or NPs) play an important role in insulin sensitivity and energy metabolism. This suggests that these hormones could be a therapeutic target in both obesity and type 2 diabetes.
Two studies were completed, the first of which involved 50 people with and without obesity. The results showed that fat tissue of obese participants had drastically lower expression of NP activation receptors than people of average weight.
The second study involved 19 patients with diabetes. This analysis found a connection between treatment with pioglitazone and a significantly lower expression of NP clearance receptors. The results suggest that medications that target pathways that result in increased NP levels could be a new way to treat metabolic disorders, including type 2 diabetes, insulin resistance, and obesity.
These findings were published in Obesity on February 27, 2016.